Cellular and Organismal Toxicity of the Anti-Cancer Small Molecule, Tolfenamic Acid: a Pre-Clinical Evaluation

• Published in: Cellular physiology and biochemistry Vol. 32; no. 3; pp. 675 - 686
• Main Authors: Sankpal, Umesh T., Lee, Chris M., Connelly, Sarah F., Kayaleh, Omer, Eslin, Don, Sutphin, Robert, Goodison, Steven, Adwan, Lina, Zawia, Nasser H., Lichtenberger, Lenard M., Basha, Riyaz
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland Cell Physiol Biochem Press GmbH & Co KG 01.01.2013
• Subjects: Animals; Antineoplastic Agents - toxicity; Body Weight - drug effects; Cell Differentiation - drug effects; Cell Line; Cell Survival - drug effects; Drug Evaluation, Preclinical; Hematocrit; Inhibitor of Apoptosis Proteins - metabolism; Intestines - pathology; Liver - pathology; Mice; Mice, Nude; Original Paper; ortho-Aminobenzoates - toxicity; Repressor Proteins - metabolism; Small molecule; Sp1; Sp1 Transcription Factor - metabolism; Stomach - pathology; Survivin; Tolfenamic acid; Toxicity; Small molecule; Survivin; Tolfenamic acid; Sp1; Toxicity

Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA o...